Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 4;15(9):2277.
doi: 10.3390/pharmaceutics15092277.

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

Seo-Yeon Kim  1 , Byung Hoon You  1 , Mingoo Bae  1 , Seung Yon Han  1 , Kiwon Jung  2   3 , Young Hee Choi  1
Affiliations

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

Seo-Yeon Kim et al. Pharmaceutics. .

Abstract

Mirabegron (MBR) is a β3-adrenoceptor agonist used for treating overactive bladder syndrome. Due to its poor solubility and low bioavailability (F), the development of novel MBR formulations has garnered increasing attention. Recently, co-amorphous dispersions of MBR, such as MBR-1,2-ethanedisulfonic acid (MBR-EFA), MBR-1,5-naphthalenedisulfonic acid (MBR-NDA), and MBR-L-pyroglutamic acid (MBR-PG), have been developed, showing improved solubility and thermodynamic stability. Nevertheless, the pharmacokinetic feasibility of these co-amorphous dispersions has not been evaluated. Therefore, this study aimed to characterize the pharmacokinetic profiles of MBR-EFA, MBR-NDA, and MBR-PG in rats and mice. Our results exhibited that relative F24h and AUC0-24h values of MBR in MBR-EFA, MBR-NDA, and MBR-PG rats were increased by 143-195% compared with the MBR rats. The absolute F24h, relative F24h, and AUC0-24h values of MBR in MBR-EFA and MBR-NDA mice were enhanced by 178-234% compared with the MBR mice. In tissue distribution, MBR was extensively distributed in the gastrointestinal tract, liver, kidneys, lung, and heart of mice. Notably, MBR distribution in the liver, kidneys, and lung was considerably high in MBR-EFA, MBR-NDA, or MBR-PG mice compared with MBR mice. These findings highlight the potential of these co-amorphous dispersions to enhance oral F of MBR.

Keywords: bioavailability; co-amorphous dispersion; mirabegron; pharmacokinetics; tissue distribution.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Chemical structures of MBR, MBR-EFA, MBR-NDA, and MBR-PG. (b) Absorption process after oral administration of MBR and its co-amorphous dispersions.
Figure 2
Figure 2
Mean (±S.D.) plasma concentrations of MBR after oral administration of MBR (□; n = 14), MBR-EFA (■; n = 10), MBR-NDA (■; n = 11), and MBR-PG (■; n = 10) at a dose of 30 mg/kg as MBR to rats. The “n” represents the number of rats used in each group.
Figure 3
Figure 3
(a) Mean (±S.D.) plasma concentrations of MBR after intravenous administration of MBR (□; n = 13) at a dose of 5 mg/kg as MBR to mice. (b) Mean (± S.D.) plasma concentrations of MBR after oral administration of MBR (□; n = 16), MBR-EFA (■; n = 15), MBR-NDA (■; n = 13), and MBR-PG (■; n = 15) at a dose of 50 mg/kg as MBR to mice. The “n” represents the number of mice used in each group.
Figure 4
Figure 4
Mean (±S.D.) (a) concentrations (µg/mL in plasma and µg/g tissue) and (b) tissue/plasma ratios of MBR (▩; n = 15 for intravenous and □; n = 15 for oral administration), MBR-EFA (■; n = 15), MBR-NDA (■; n = 15), and MBR-PG (■; n = 15) in various tissues at 0.5, 2, 4, 8, and 10 h after intravenous administration of MBR (5 mg/kg as MBR) and oral administration (50 mg/kg as MBR) of MBR, MBR-EFA, MBR-NDA, and MBR-PG to mice. * MBR-NDA and MBR-PG mice were significantly different (p < 0.05) from MBR mice. ** MBR-EFA and MBR-PG mice were significantly different (p < 0.05) from MBR mice. + MBR-NDA mice were significantly different (p < 0.05) from MBR mice. The “n” represents the number of mice used in each group.
Figure 4
Figure 4
Mean (±S.D.) (a) concentrations (µg/mL in plasma and µg/g tissue) and (b) tissue/plasma ratios of MBR (▩; n = 15 for intravenous and □; n = 15 for oral administration), MBR-EFA (■; n = 15), MBR-NDA (■; n = 15), and MBR-PG (■; n = 15) in various tissues at 0.5, 2, 4, 8, and 10 h after intravenous administration of MBR (5 mg/kg as MBR) and oral administration (50 mg/kg as MBR) of MBR, MBR-EFA, MBR-NDA, and MBR-PG to mice. * MBR-NDA and MBR-PG mice were significantly different (p < 0.05) from MBR mice. ** MBR-EFA and MBR-PG mice were significantly different (p < 0.05) from MBR mice. + MBR-NDA mice were significantly different (p < 0.05) from MBR mice. The “n” represents the number of mice used in each group.
See this image and copyright information in PMC

References

    1. Chen H.L., Chen T.C., Chang H.M., Juan Y.S., Huang W.H., Pan H.F., Chang Y.C., Wu C.M., Wang Y.L., Lee H.Y. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: A systematic review and meta-analysis. World J. Urol. 2018;36:1285–1297. doi: 10.1007/s00345-018-2268-9. - DOI - PubMed
    1. Kelleher C., Hakimi Z., Zur R., Siddiqui E., Maman K., Aballéa S., Nazir J., Chapple C. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network meta-analysis. Eur. Urol. 2018;74:324–333. doi: 10.1016/j.eururo.2018.03.020. - DOI - PubMed
    1. Alessio B., Pietro A., Emanuele A. Crystalline Forms of Mirabegron Acetate Salt. 2-857389. EP Patent. 2015 August 4;
    1. FDA Clinical Pharmacology and Biopharmaceutics Review(s) Application Number: 202611Orig1s000. [(accessed on 7 March 2012)]; Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000C....
    1. Patel D.A., Patel D.J. Physicochemical characterization and in vitro dissolution enhancement of mirabegron using solid dispersion method. World J. Pharm. 2018;7:973–991.

LinkOut - more resources